Inter-individual variability in carcinogen metabolism has been attributed in part to the polymorphic expression of several phase I and II detoxification enzymes. The role of these genetic polymorphisms in cancer susceptibility has been most extensively evaluated for isozymes of cytochrome P450 (CYP1A1, CYP2D6, and CYP2E1), N-acetyltransferase (NAT1 and NAT2), glutathione S-transferase (GSTM1, GSTT1, and GSTP1), microsomal epoxide hydrolase, and NAD(P)H:quinone oxidoreductase. Our understanding of the genetic basis of cancer risk has been enhanced most recently by establishment of genotype-phenotype correlations in humans and identification of numerous diverse factors, both genetic and environmental, that can modify risk.
KeywordsCancer Risk Breast Cancer Risk Cancer Susceptibility Oral Squamous Cell Carcinoma Lung Cancer Risk
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 2.Whitlock JP: Induction of cytochrome P4501A1. Annual Rev Pharmacol Toxicol 1999, 39:103–125. This recent comprehensive review summarizes our current understanding of the regulation of CYP1A1. Implications for enhanced carcinogen activation and cancer susceptibility are discussed.CrossRefGoogle Scholar
- 4.Iba MM, Scholl H, Fung J, et al.: Induction of pulmonary CYP1A1 by nicotine. Xenobiotica 1998, 28:827–843. Extensive animal data are presented to support the classification of nicotine as a potent inducer of CYP1A1. In addition to further elucidating the mechanism by which cigarette smoke induces CYP1A1, the results from this study imply that nicotine replacement products could increase cancer risk.PubMedCrossRefGoogle Scholar
- 5.Benet LZ, Kroetz DL, Sheiner LB: Pharmacokinetics. In Goodman and Gilman’s Pharmacological Basis of Therapeutics, edn 9. Edited by Hardman LG, Goodman Gilman A, Limbird LE. New York: McGraw-Hill; 1996:3–27.Google Scholar
- 6.Wolf CR, Smith G: Cytochrome P450 CYP2D6. In Metabolic Polymorphisms and Susceptibility to Cancer. Edited by Vineis P, Malats N, Lang M, d’Errico A, et al. Lyon, France: International Agency for Research on Cancer; 1999:209–229. This new release from IARC is an excellent, comprehensive overview of all of the metabolic polymorphisms that have been identified to date. The potential contribution of each to cancer susceptibility is discussed in detail.Google Scholar
- 12.Moisio ML, Sistonen P, Mecklin JP, et al.: Genetic polymorphisms in carcinogen metabolism and their association to hereditary nonpolyposis colon cancer. Gastroenterology 1998, 115:1387–1394. This unique study evaluates genetic polymorphisms in individuals with a heritable cancer syndrome. The results suggest that metabolic polymorphisms can modulate the cancer phenotype among individuals with a mutation in the mismatch repair gene MLH1.PubMedCrossRefGoogle Scholar
- 18.Ali-Osman F, Akande N, Mao J: Molecular cloning, characterization and expression of novel functionally different human glutathione S-transferase-P-1 gene variant. Proceedings of the International ISSX Workshop on Glutathione S-Transferase 1995, 7:38.Google Scholar
- 35.Dresler CM, Fratelli C, Babb J, et al.: Women with a CYP1A1 polymorphism are at significantly increased risk of developing lung cancer. Proc Am Assoc Cancer Res 1999, 40:567.Google Scholar
- 36.Mollerup S, Ryberg D, Hewer A, et al.: Sex differences in lung CYP1A1 expression and DNA adduct levels among lung cancer patients. Cancer Res 1999, 59:3317–3320. This study represents the first report of the functional significance of gender differences in CYP1A1 expression in humans. Significantly higher levels of DNA adducts were present in normal lung tissue from female smokers (vs males) and correlated directly with increased CYP1A1 activity.PubMedGoogle Scholar